NCT01970488View on ClinicalTrials.gov

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

October 18, 2013

Primary Completion Date

August 14, 2014

Study Completion Date

March 18, 2015

Conditions
Psoriasis
Interventions
BIOLOGICAL

Adalimumab

Administered by subcutaneous injection

BIOLOGICAL

ABP 501

Administered by subcutaneous injection

Trial Locations (3)

2065

Research Site, Saint Leonards

4400

Research Site, Nyíregyháza

A1A 5E8

Research Site, St. John's

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01970488 - Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter